Company intelligence / Profile preview

Hotspot Lunch

Boston/Cambridge area, Massachusetts, United Statesmelbasrestaurant.com ↗

Ownership: Private
Employees: ~75
Development stage: Other

Overview

HotSpot Therapeutics is a clinical-stage biotech developing first-in-class oral small molecule allosteric therapies targeting regulatory sites ("natural hotspots") on proteins. Its lead programs target cancer and autoimmune indications, with preclinical data presented for novel scaffolding inhibitors such as MALT1. The company leverages AI-driven discovery and bespoke chemistry to systematically identify and drug these allosteric sites. No late-stage or commercial results have been reported publicly.

Therapeutic areas: ImmunologyMetabolic DisordersOncology
Modalities: Small moleculeAllosteric therapy
Industry: Biotech

Partnerships

Caris Life Sciences

Beyond the preview

Go deeper on Hotspot Lunch.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hotspot Lunch.

Explore the full profile